Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE studyGuy Young, Tadashi Matsushita, Flora Peyvandi et al.|Blood|2025Cited by 38
High treatment compliance and tolerability with fitusiran antithrombin-based dose regimen in people with hemophilia A or B, with or without inhibitors: ATLAS-OLE studyMindy Simpson, Erin Cockrell, Chia-Yau Chang et al.|Blood|2025Cited by 0